The DOI matches its Crossref record.
Targeted protein degraders crowd into the clinic
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although some have entered clinical trials with a primary focus on PROTAC, the diverse range of protein regulation methods has undoubtedly laid a robust foundation for developing drugs targeting previously undruggable proteins.477–479”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [478]
In the citing paper
“Indeed, this exciting technology is currently transitioning to the clinic, with several PROTACs now in clinical trials.16,31”
From Chasing molecular glue degraders: screening approaches (2022) · cites this paper as [31]
In the citing paper
“Chemical diversification of known glue degraders, especially IMiDs, has delivered derivatives that are even approaching the clinic.16,31”
From Chasing molecular glue degraders: screening approaches (2022) · cites this paper as [31]
In the citing paper
“The Helios glue degrader DKY709 (Fig. 8) from Novartis is in Phase I for solid cancers (currently tested as monotherapy and in combination with spartalizumab, an anti-PD-1).16,31”
From Chasing molecular glue degraders: screening approaches (2022) · cites this paper as [31]
In the citing paper
“Twenty years after its theoretical conception, at least 15 targeted protein degraders, among them heterobifunctional PROTACs and molecular glues, had entered the clinic by the end of 2021 (ref.30) (Tables 1,2), and many more are expected to follow.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [30]
In the citing paper
“DT2216 is in phase I trials30”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [30]
In the citing paper
“Degrader drugs currently on the market (the IMiD class) and the overwhelming majority of newly developed PROTACs and molecular glue compounds currently in clinical trials (Tables 1,2) target various types of cancer30,163.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [30]
Citations
Cites
Still being checked.
Cited by
Sorted by citations
Items 401–423 of 423
BindingDB (2023) · UC San Diego · doi:10.7270/q2t157nq
BindingDB (2024) · UC San Diego · doi:10.7270/q2dz0drt
BindingDB Entry 50016327: Selectivity through Targeted Protein Degradation (TPD).
BindingDB (2023) · UC San Diego · doi:10.7270/q22n568r
BindingDB (2023) · UC San Diego · doi:10.7270/q2v128pr
BindingDB (2024) · UC San Diego · doi:10.7270/q2vh5t9d
BindingDB (2024) · UC San Diego · doi:10.7270/q2pv6qt5
BindingDB Entry 50019557: Discovery of NAFLD-Improving Agents by Promoting the Degradation of Keap1.
BindingDB (2024) · UC San Diego · doi:10.7270/q2s186w8
Metadata
- Authors
- Mullard, A.
- Corresponding author
- Mullard, Asher
- Venue
- Nature Reviews Drug Discovery
- Published
- 2021-03-18
- Volume
- 20
- Issue
- 4
- Pages
- 247-250
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W3136448722
- Cited by
- 409
- References
- 0
- Citations by year
- 2026: 42 · 2025: 51 · 2024: 78 · 2023: 85 · 2022: 104 · 2021: 48
- Type
- other
- Language
- en
- Open access
- closed
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- targeted protein degradation, PROTACs, heterobifunctional degraders, molecular glues, clinical development, drug approval
- MeSH terms
- Drug Development, Animals, Humans, Proteins, Drug Discovery, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
